Rucaparib
|
|
|
- CAS-Nr.
- 283173-50-2
- Englisch Name:
- Rucaparib
- Synonyma:
- Rucaparib Base;8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one;Rikapbu;AG-14447;AG014447;Rucaparib;AG 014447;PF-01367388;AG 014447;AG014447;Rucaparib impurity
- CBNumber:
- CB51475507
- Summenformel:
- C19H18FN3O
- Molgewicht:
- 323.36
- MOL-Datei:
- 283173-50-2.mol
|
Rucaparib Eigenschaften
- Schmelzpunkt:
- 187 - 189°C
- Siedepunkt:
- 625.2±55.0 °C(Predicted)
- Dichte
- 1.281
- storage temp.
- 2-8°C(protect from light)
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Yellow solid.
- pka
- 14.10±0.20(Predicted)
- Farbe
- Pale Yellow to Yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H361 |
Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Reproduktionstoxizit?t |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P281 |
Vorgeschriebene pers?nliche Schutzausrüstung verwenden. |
| P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Rucaparib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Rucaparib was
approved in the US as an oral treatment for advanced ovarian
cancer. Development of rucaparib began with collaborations
between Cancer Research UK and Agouron Pharmaceuticals
(later acquired by Pfizer). Global development rights for
rucaparib were ultimately granted to Clovis Oncology via a
licensing agreement from Pfizer. To qualify for treatment with
rucaparib monotherapy, patients must demonstrate deleterious
breast cancer (BRCA) mutation (germline and/or somatic)-
associated advanced ovarian cancer and also must have
previously been treated with two or more chemotherapy
regimens. Rucaparib functions as a small molecule poly(ADPribose)
polymerase (PARP) inhibitor, which plays an important
role in DNA repair. This newly approved drug displays
nanomolar potency against PARP-1, -2, and -3 enzymes,
which translates into improved efficacy over alternative
therapies such as olaparib or niraparib. Furthermore,
rucaparib is also known to cause vasodilation, which is thought
to induce tumor perfusion and increased accumulation of the
drug in cancer cells. Although rucaparib shows higher
cytotoxicity in cancer cells with mutation of BRCA1/2 genes
and other DNA repair genes, reduced tumor growth was
observed in mouse xenograft models of human cancers with
and without BRCA mutations.Rucaparib is also being
pursued as a treatment for breast cancer and has displayed
promising initial results in trials for pancreatic cancer.
Verwenden
Rucaparib is PARP1 inhibitor. It can be used in biological study of chemical screening to identify drugs that enhance or mitigate cellular responses to antibody-toxin fusion proteins using human B cell precursor leukemia cells and cervical adenocarcinoma cells.
Rucaparib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
methyl (4-(8-fluoro-1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)benzyl)(methyl)carbamate
8-fluoro-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
(4-BROMOBENZYL)METHYLAMINE
Downstream Produkte
Rucaparib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 198)Lieferanten
283173-50-2()Verwandte Suche:
Benzamid
[4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacen-2-carboxamidmonohydrochlorid
Chinazolin-4(1H)-on
4-Aminonaphthalin-1,8-dicarboximid
m-Aminobenzamid
- 8-FLUOR-2-{4-[(METHYLAMINO)METHYL]FENYL}-1,3,4,5-TETRAHYDRO-6HAZEPINO[5,4,3-CD]INDOOL-6-ON
- 8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one
- 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-
- 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one
- 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
- Rucaparib
- rucaparib (PARP inhibitor) ORPHAN DRUG
- PF-01367388
- Rucaparib impurity
- 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tet...
- AG-14447
- Rucaparib free base
- AG-014699;PF-01367338; AG 014699;PF 01367338; AG014699;PF01367338
- Rucaparib(AG-014447)
- Rikapbu
- AG014447
- AG 014447;AG014447
- AG 014447
- 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one
- Rucaparib Base
- 8-Fluoro-2-[4-[(methylamino)methyl]phenyl]-4,5-dihydroazepino[5,4,3-cd]indol-6(3H)-one
- AG-14447|||PF-01367338|||AG014699
- 283173-50-2
